Monolithic Tofacitinib Tablet Without Functional Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral formulations of tofacitinib, such as XELJANZ XR®, are costly to manufacture due to the complexity of osmotic pump technology and face challenges in achieving consistent drug release profiles, particularly for highly soluble compounds, leading to variability in bioavailability.
Innovation Solution
A monolithic tablet formulation using a swellable hydrophilic matrix with a water soluble pH-independent gelling control release polymer, without a functional coating, to achieve controlled release of tofacitinib, mimicking the osmotic pump system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If osmotic pump technology is used to achieve controlled release of tofacitinib, then drug release profile consistency is improved, but manufacturing cost and device complexity increase significantly
Solution Approach 1:
The patent extracts and eliminates the complex functional coating layer from the osmotic pump system, retaining only the essential semi-permeable membrane and core components. This simplification maintains the controlled release function while dramatically reducing manufacturing complexity and cost, directly resolving the contradiction between release consistency and device complexity
Solution Approach 2:
The patent replaces expensive, complex osmotic pump systems with a simpler, more economical tablet formulation that achieves comparable controlled release through basic excipient combinations and standard compression techniques, making the technology accessible to more manufacturers and patients
2Productivity
If laser drilling is used to create orifices in osmotic pumps, then manufacturing throughput and precision are improved, but system cost and manufacturing complexity increase
Solution Approach 1:
The patent replaces complex laser drilling machinery with conventional mechanical compression and formulation techniques. The controlled release function is achieved through the tablet's intrinsic properties (hydrophilic polymer matrix, pore formers, and excipient interactions) rather than through precisely drilled orifices, eliminating the need for expensive laser equipment while maintaining productivity
Solution Approach 2:
The patent removes the orifice creation step entirely from the manufacturing process by using a coating-free osmotic pump design where drug release occurs through the semi-permeable membrane without requiring drilled holes, thereby eliminating the need for laser drilling equipment and simplifying the manufacturing system
3Reliability
If functional coating is applied to osmotic pump tablets, then drug release control is improved, but manufacturing cost and process complexity increase
Solution Approach 1:
The patent extracts and eliminates the functional coating layer from the tablet formulation, achieving controlled release through the inherent properties of the core components (hydrophilic polymer, pore formers, and excipient interactions). This removal of the coating step simplifies the manufacturing process, reduces costs, and eliminates associated process complexities while maintaining reliable drug release control
Solution Approach 2:
The patent replaces expensive functional coating materials and application processes with simpler, more economical tablet excipients and formulation techniques that achieve comparable controlled release functionality without requiring complex coating equipment or multi-step manufacturing processes
4Strength
If non-erodible material is used in monolithic tablets, then structural integrity is improved, but water penetration and hydration rate decrease
Solution Approach 1:
The patent applies local quality by incorporating hydrophilic polymer and pore formers specifically in regions where water penetration is needed, while maintaining non-erodible material in areas requiring structural integrity. This spatial differentiation of material properties enables simultaneous achievement of both structural strength and adequate hydration rates through targeted material placement within the tablet matrix
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monolithic tablet provides a cost-effective and bioequivalent drug release profile to XELJANZ XR®, ensuring consistent drug delivery over 6 hours with 40-60% release in 2 hours and at least 80% release in 6 hours, overcoming manufacturing inefficiencies and variability.
Implementation Method 1
A monolithic tablet formulation using a swellable hydrophilic matrix
Implementation Method 2
ensuring consistent drug delivery over 6 hours
Implementation Method 3
water soluble pH-independent gelling control release polymer
Implementation Method 4
pH-independent gelling control release polymer
Implementation Method 5
provides a cost-effective and bioequivalent drug release profile to XELJANZ XR®, ensuring consistent drug delivery
Data Source
AI summary
The present invention relates to a monolithic tablet composition for oral administration of tofacitinib or a pharmaceutically acceptable salt thereof, without a functional coating.